1. Oxygen–ozone treatment and COVID-19: antioxidants targeting endothelia lead the scenery
- Author
-
Giovanni Ricevuti, Angelica Varesi, and Salvatore Chirumbolo
- Subjects
Blood Platelets ,2019-20 coronavirus outbreak ,Ozone ,Coronavirus disease 2019 (COVID-19) ,Neutrophils ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Critical Illness ,Ce - Letter to the Editor ,chemistry.chemical_element ,Oxygen ,Antioxidants ,Monocytes ,Microbiology ,chemistry.chemical_compound ,Fibrinolytic Agents ,Internal Medicine ,Medicine ,Humans ,Blood Coagulation ,Lung ,Venous Thrombosis ,business.industry ,SARS-CoV-2 ,COVID-19 ,Immunity, Innate ,n/a ,chemistry ,Emergency Medicine ,Endothelium, Vascular ,business ,Cytokine Release Syndrome - Abstract
Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe disease show hyperactivation of the immune system, which can affect multiple organs besides the lungs. Here, we propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels. Microthrombotic complications may contribute to acute respiratory distress syndrome (ARDS) and other organ dysfunctions. Therapeutic strategies aimed at reducing immunothrombosis may therefore be useful. Several antithrombotic and immunomodulating drugs have been proposed as candidates to treat patients with SARS-CoV-2 infection. The growing understanding of SARS-CoV-2 infection pathogenesis and how it contributes to critical illness and its complications may help to improve risk stratification and develop targeted therapies to reduce the acute and long-term consequences of this disease.
- Published
- 2021